Equine hepatitis is inflammation of the liver in horses, and it is best understood as a final common pathway rather than a single disease. Viruses, bacteria, toxins, drugs, and metabolic disorders can each trigger it. Because the liver has large functional reserves, clinical signs often appear only after substantial damage has occurred. Recognizing the difference between acute and chronic forms, and between infectious and toxic causes, determines whether a horse recovers fully or faces long-term management.
Mechanism: Why the Equine Liver Fails Quietly
The liver receives roughly 70 percent of its blood supply through the portal vein, which carries everything absorbed from the gut directly to hepatocytes for processing. This anatomy explains why ingested toxins and gut-derived bacteria reach the liver first. Hepatocytes handle detoxification, protein synthesis, bile production, and glucose storage simultaneously. When inflammatory cells infiltrate hepatic tissue, they release cytokines and reactive oxygen species that damage cell membranes. The result is impaired bile flow, leaky capillaries, and reduced synthetic capacity.
Equine hepatitis takes several forms. Acute hepatitis involves sudden widespread necrosis, often from toxins or infection. Chronic hepatitis involves ongoing low-grade inflammation with progressive fibrosis. Cholangiohepatitis targets the bile ducts and is often bacterial. Pyrrolizidine alkaloid toxicity produces a distinctive megalocytosis, in which hepatocytes enlarge but cannot divide, leading to delayed failure weeks after ingestion. The liver's regenerative capacity masks early damage: up to 70 percent of functional tissue can be lost before serum markers or clinical signs reflect it. This latency is why horses often present with advanced disease.
Quantified Context: How Common and How Serious
Equine liver disease is uncommon in general practice but overrepresented in certain populations. Serum biochemistry panels in apparently healthy horses show elevated liver enzymes in roughly 1 to 5 percent of cases, and most of those elevations are mild and transient. Gamma-glutamyl transferase (GGT) and sorbitol dehydrogenase (SDH) are the most sensitive indicators of equine hepatic injury. SDH rises within hours of acute hepatocellular damage and falls quickly because of its short half-life. GGT reflects biliary epithelial damage and stays elevated longer, making it useful for tracking cholangiohepatitis.
Reference ranges vary by laboratory, so trends matter more than single values. A common interpretive threshold is enzyme activity exceeding two to three times the upper reference limit, which warrants investigation rather than observation. Severe elevations, often ten times the upper limit or more, correlate with significant necrosis. Serum bile acids above 20 micromoles per liter suggest impaired hepatic function rather than simple injury. Albumin and clotting factors fall only with advanced synthetic failure, which is a late and grave sign.
Pyrrolizidine alkaloid toxicity from tansy ragwort, riddell groundsel, and similar plants is among the most documented toxic causes worldwide. The alkaloids are bioactivated by hepatic cytochrome P450 enzymes into pyrroles that bind cellular proteins and halt mitosis. Horses are more susceptible than cattle, and cumulative exposure over weeks produces the classic delayed presentation. The toxic dose varies by plant species and growing conditions, so no single threshold applies; avoidance is the only reliable prevention.
Acute Versus Chronic Hepatitis: A Comparison
| Feature | Acute hepatitis | Chronic hepatitis | Cholangiohepatitis | Pyrrolizidine toxicity |
|---|---|---|---|---|
| Typical trigger | Toxin, infection, drug | Immune-mediated, ongoing insult | Bacterial ascending infection | Plant alkaloids |
| Onset | Hours to days | Weeks to months | Variable, often insidious | Weeks after exposure |
| Key enzyme pattern | SDH markedly elevated | GGT and bile acids elevated | GGT disproportionately high | GGT elevated, delayed |
| Clinical signs | Fever, jaundice, depression | Weight loss, poor performance | Fever, colic signs | Weight loss, photosensitization |
| Prognosis | Guarded to fair | Guarded, often progressive | Fair with targeted therapy | Poor once clinical |
| Reversibility | Often reversible if insult removed | Fibrosis may be permanent | Good if bacteria identified | Megalocytosis irreversible |
Edge Cases: When Hepatitis Masks Something Else
Several conditions imitate hepatitis without primarily involving the liver. Right dorsal colitis can produce hypoproteinemia and edema that resemble hepatic failure. Cardiac disease with right-sided heart failure causes hepatic congestion and elevated liver enzymes from passive backup rather than primary inflammation. Hyperlipemia in ponies and donkeys produces marked hepatic lipidosis with enzyme elevations that resolve with metabolic correction. Theiler's disease, an acute hepatitis historically linked to equine serum administration, remains poorly understood but is now rare.
A counterintuitive detail deserves emphasis: jaundice in horses is not synonymous with liver failure. Anorexia alone can raise unconjugated bilirubin without any hepatic pathology, because reduced food intake impairs bilirubin uptake. Hemolysis from immune-mediated disease or piroplasmosis also produces jaundice while liver function remains intact. Fractionating bilirubin and checking a complete blood count separates these causes before committing to a hepatic workup. This distinction prevents unnecessary diagnostics and misplaced concern.
Drug-induced liver injury is underrecognized in horses. Certain anthelmintics, antimicrobials, and nonsteroidal anti-inflammatory drugs have been implicated in individual cases, though causality is often presumptive. The pattern is typically acute and resolves with withdrawal of the suspected agent. Any horse developing enzyme elevations during treatment warrants drug review before assuming an infectious cause.
Red-Flag Findings That Require Prompt Veterinary Attention
Jaundice combined with lethargy, fever, or loss of appetite lasting more than 24 hours Serum GGT or SDH above three times the upper reference limit on any single sample Hepatic encephalopathy signs: head pressing, circling, aimless wandering, or behavioral change Photosensitization with skin sloughing on unpigmented areas, suggesting liver dysfunction Coagulopathy signs such as prolonged bleeding from minor wounds, indicating synthetic failure Known exposure to tansy ragwort or other pyrrolizidine-containing plants within the preceding eight weeks
Misconceptions and Professional Caveats
The most persistent misconception is that a single normal liver panel excludes hepatic disease. Because of reserve capacity, resting enzyme values can be normal in horses with compensated chronic fibrosis. Dynamic testing with bile acid challenge or liver biopsy may be needed when clinical suspicion remains high despite normal baseline results. Practitioners who rely only on screening panels can miss significant pathology.
A second misconception treats all liver enzyme elevations as equally urgent. Mild, transient rises in GGT after transport, fasting, or minor illness are common and usually resolve within two weeks. The pattern and trajectory, not the isolated number, guide interpretation. Conversely, a horse with normal enzymes can still have advanced cirrhosis if the remaining hepatocytes are not actively leaking.
A professional caveat concerns biopsy. Liver biopsy remains the diagnostic standard for distinguishing inflammatory, toxic, and neoplastic disease, but it carries bleeding risk, particularly when clotting factors are depleted. Coagulation status should be assessed before the procedure. Ultrasound-guided biopsy improves safety but does not eliminate risk. Sampling error also occurs when disease is patchy.
Practical Actions and Monitoring Thresholds
Owners managing a horse with suspected hepatitis should prioritize forage quality, pasture inspection, and medication review. Remove access to known toxic plants and confirm hay sources. Any new drug or supplement introduced in the preceding eight weeks should be documented and discussed with the veterinarian. For horses with confirmed elevation, a practical monitoring schedule uses repeat biochemistry at two-week intervals until values trend downward.
Concrete steps include the following. Record body weight weekly, because loss of 5 percent or more signals progression. Monitor water intake, which falls with hepatic encephalopathy risk. Recheck GGT and SDH together, since their different time courses reveal whether biliary or hepatocellular disease predominates. Check serum bile acids when albumin or bilirubin trends abnormal. Avoid unnecessary medications during recovery; the inflamed liver metabolizes drugs unpredictably.
Thresholds should be reconciled explicitly. Enzyme elevations more than two to three times the upper reference limit justify investigation; tenfold elevations justify urgent workup. Serum bile acids above 20 micromoles per liter justify functional assessment. Albumin below the reference range with prolonged clotting times justifies prognostic caution. The same horse can cross several thresholds at different times, so serial measurement matters more than any single cutoff. Owners should ask for numerical results and trend them, not just "normal" or "abnormal" labels.
Limitations of Current Knowledge
Equine hepatitis lacks large prospective studies, and much of the evidence base comes from case series and retrospective reviews. Reference intervals differ between laboratories and vary with age, breed, and management. The relationship between subclinical enzyme elevations and long-term outcome is not established. Theiler's disease has no identified causal agent despite decades of investigation. No vaccine exists for infectious hepatitis in horses. Prophylaxis rests on biosecurity, plant control, and judicious medication use rather than specific immunity. Treatment decisions require veterinary assessment of the individual horse, and no single protocol applies across causes.